Schizophrenia

GECKO on the run for HTML - June 2014

 

 

  Download the PDF here

 Schizophrenia may be isolated or associated with physical and/or learning differences (syndromic).

Isolated schizophrenia has complex inheritance. There are many potential susceptibility genes and genomic regions under investigation. Development of disease likely depends on the interaction of genetic susceptibility and other factors. Although empiric risks for relatives to develop schizophrenia exist, no clinical genetic test is currently available. Genetic counselling is an option for affected individuals and those with a family history of schizophrenia.

About 1-2% of individuals with schizophrenia have a syndrome caused by a subtle chromosome abnormality called 22q11 deletion. Individuals with schizophrenia and a history of congenital anomalies such as cleft palate or heart defects, and/or speech/learning difficulties, should be offered genetics referral for evaluation for 22q11 deletion syndrome. Genetic counselling and testing may lead to specific management plans for affected individuals and may facilitate reproductive planning decisions for families.

Updated January 2014

 

WHAT IS SCHIZOPHRENIA?

Schizophrenia is diagnosed in about 1% of the population; males and females are equally affected. Onset is typically in the early 20s in males and late 20s in females. Early symptoms are social withdrawal, loss of previous interests, unusual thinking/behaviour, deterioration of hygiene/grooming, depression, irritability, anxiety and sleep disturbances. Late symptoms are hallucinations, delusions and disorganized behaviour, decrease in emotional range, poverty of speech, loss of interest and lack of drive. Cognitive symptoms are deficits in attention and executive functions like organization & abstract thinking. Treatment includes anti-psychotics such as haloperidol, risperidone, and olanzapine, and supportive therapy.1,2

Heritability of schizophrenia is high (~80%). First-degree relatives (children, parents or siblings) of an affected individual have about a 10-fold increased risk of developing schizophrenia or schizophrenia spectrum disorders (schizotypal personality disorder, paranoid personality disorder, schizoaffective disorder, unipolar/major depression) – see Table 1. No single gene is known to contribute a major risk for schizophrenia. Genetic studies suggest multiple genes and/or genomic regions, each making a small contribution to the risk of schizophrenia. The accumulation of genetic susceptibility factors plus other environmental, developmental and epigenetic factors lead to disease. Many potential susceptibility genes and genetic regions have been identified, including small chromosome duplications, deletions and copy number variants. More studies are needed to determine how these genomic regions interact with other factors to contribute to an individual’s risk to develop schizophrenia. Because of the stigma of psychiatric illness some individuals may be unwilling to discuss or unaware of their family history. There are few data on the risk for psychiatric illness where multiple family members are affected.2,3,4

 

Schizophrenia On the run - Table 1 - Jan 2014

Table 1. Estimated empirical risk for schizophrenia based on family history.

 

RED FLAGS TO CONSIDER GENETIC TESTING OR GENETIC CONSULTATION

If an individual with schizophrenia has other health problems (such as a history of congenital anomalies, learning or speech difficulties), consider referring to a genetics clinic for an evaluation for 22q11 deletion syndrome (also known as velocardiofacial syndrome or DiGeorge syndrome). Only 1-2% of individuals with schizophrenia are estimated to have 22q11 deletion syndrome. 22q11 deletion syndrome has variable features, including a subtle yet characteristic facial appearance, physical defects (heart, palate), endocrine disorders (hypocalcaemia, hypothyroidism), speech (hypernasal) and learning difficulties. Approximately 25% of individuals with 22q11 deletion syndrome develop schizophrenia and about half have other psychiatric illnesses including attention deficit disorder, autism spectrum disorder, general anxiety and mood disorders. Genetic testing (chromosomal microarray [CMA], fluorescent in situ hybridization [FISH]) will detect ~95% of cases. Identification of the 22q11 deletion facilitates more specific anticipatory guidance and management. Many individuals with this syndrome have unrecognized health problems, for example, seizures may not be recognized as a symptom of hypocalcemia, recurrent infections may be caused by immune deficiency, or an unrecognized cardiac structural defect may exist. Families with an affected individual may also want genetic testing or counselling for family planning purposes.5

Although there is no genetic testing for isolated (non-syndromic) schizophrenia, genetic counselling may offer the following benefits:6

  • Provision of empiric recurrence risks to family members which can help with adjustment to personal risk and family planning (see Table 1)
  • Education of family members about psychiatric illness
  • Identification of the rare syndromic cause of schizophrenia

 

WHAT DOES THE GENETIC TEST RESULT MEAN?

Genetic testing is not available or routinely recommended for isolated schizophrenia. Testing for the susceptibility genes/genomic regions for schizophrenia has no clinical utility until it is determined how these genes/genomic regions modify an individual’s risk of developing schizophrenia.6,7 Be wary of direct-to-consumer marketing of genetic tests for psychiatric illness. The clinical utility of these tests has not been established.

Confirmation of the 22q11 deletion in an individual with schizophrenia allows the physician to plan evaluations looking for associated medical problems5. Close relatives may want to have testing to determine if the deletion is de novo or familial. The affected individual can use this information for family planning and prenatal diagnostic purposes.

 

For a recent review article on schizophrenia see Rethelyi JM et al., Genes and environments in schizophrenia: The different pieces of a manifold puzzle. Neurosci Biobehav Rev 2013; 37(10)Part 1: 2424-2437.

Click here to connect to your local genetics centre.

 

References

[1] Schultz SH, North SW, Shields CG. Schizophrenia: A review. Am Fam Physician 2007; 75:1821-1829
[2] Austin JC and Honer WG. The potential impact of genetic counseling for mental illness. Clin Genet 2005; 67;134-142
[3] Maric NP and Svrakic DM. Why schizophrenia genetics needs epigenetics: a review. Psychiatria Danubina 2012; 24(1): 2-18
[4] Rethelyi JM, Benkovits J, Bitter I. Genes and environments in schizophrenia: The different pieces of a manifold puzzle. Neurosci Biobehav Rev 2013; 37(10)Part 1: 2424-2437
[5] McDonald-McGinn DM, Emanuel BS, Zackai EH. 22q11 Deletion Syndrome Gene Reviews http://www.ncbi.nlm.nih.gov/books/NBK1523/ Last update February 28, 2013. Accessed on January 14, 2014.
[6] Austin JC, Peay HL. Applications and limitations of empiric data in provision of recurrence risks for schizophrenia: a practical review for healthcare professionals providing clinical psychiatric genetics consultations. Clin Genet 2006; 70:177-187
[7] Mitchell PB, Meiser B, Wilde A, et al. Predictive and diagnostic genetic testing in psychiatry. Clin Lab Med 2010 Dec;30(4):829-46

Other resources: The Schizophrenia Society of Canada http://www.schizophrenia.ca/

Authors: AL Rideout MS (C)CGC, JE Allanson MD FRCPC, S Morrison MS CGC and JC Carroll MD CCFP

Updated from the original Gene Messenger developed for the GenetiKit research project.
GenetiKit team: Principal Investigators: Carroll JC, Allanson J, Wilson BJ, Co-Investigators: Blaine S, Cremin C, Dorman H, Gibbons C, Graham GE, Graham I, Grimshaw J, Honeywell C, Meschino WS, Permaul J, Wilson BJ.

GEC-KO on the run is for educational purposes only and should not be used as a substitute for clinical judgement. GEC-KO aims to aid the practicing clinician by providing informed opinions regarding genetic services that have been developed in a rigorous and evidence-based manner. Physicians must use their own clinical judgement in addition to published articles and the information presented herein. GEC-KO assumes no responsibility or liability resulting from the use of information contained herein.